Corcept Therapeutics (CORT) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.36
- EPS estimate
- $0.02
- EPS surprise
- +1381.48%
- Revenue surprise
- +15.83%
- Revenue
- $256.1M
- Revenue estimate
- $221.1M
- Reported
- Jul 29, 2026
Corcept Therapeutics reported Q2 2026 results on July 29, 2026. Earnings per share were $0.36, against an estimate of $0.02, a surprise of 1381.48%. Revenue was $256.1 million, beating the $221.1 million consensus by 15.83% and setting a high for the table. Compared with Q2 2025, EPS rose about 24% from $0.29 and revenue rose about 32% from $194.4 million.
The quarter followed a loss. In Q1 2026, Corcept lost $0.30 per share against an expected loss of $0.11, the only loss in the table. Revenue has grown every year shown, from $401.9 million in 2022 to $761.3 million in 2025. Annual EPS has been less steady: $0.88 in 2022, $0.95 in 2023, $1.24 in 2024 and $0.82 in 2025. The first half of 2026 adds up to $0.06 per share, against $0.46 a year earlier. Over the last 20 quarters, Corcept beat the EPS estimate 13 times and missed 7 times.
Corcept reported Q3 between October 30 and November 4 in each of the past five years. That points to late October or early November 2026 for the next report. It will show whether the return to profit in Q2 holds.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 29, 2026 | $0.02 | $0.36 | +1381.48% | $256.1M | SEC |
| Q1 2026 | Apr 30, 2026 | −$0.11 | −$0.30 | −176.50% | $164.9M | SEC |
| Q4 2025 | Feb 24, 2026 | $0.33 | $0.20 | −39.30% | $202.1M | SEC |
| Q3 2025 | Nov 4, 2025 | $0.16 | $0.16 | −2.26% | $207.6M | SEC |
| Q2 2025 | Jul 31, 2025 | $0.19 | $0.29 | +54.67% | $194.4M | SEC |
| Q1 2025 | May 5, 2025 | $0.14 | $0.17 | +19.30% | $157.2M | SEC |
| Q4 2024 | Feb 26, 2025 | $0.43 | $0.26 | −39.01% | $181.9M | SEC |
| Q3 2024 | Oct 30, 2024 | $0.28 | $0.41 | +45.44% | $182.5M | SEC |
| Q2 2024 | Jul 29, 2024 | $0.23 | $0.32 | +39.13% | $163.8M | SEC |
| Q1 2024 | May 1, 2024 | $0.22 | $0.25 | +13.64% | $146.8M | SEC |
| Q4 2023 | Feb 15, 2024 | $0.26 | $0.28 | +8.49% | $135.4M | SEC |
| Q3 2023 | Nov 1, 2023 | $0.22 | $0.28 | +28.26% | $123.6M | SEC |
| Q2 2023 | Aug 2, 2023 | $0.15 | $0.25 | +66.67% | $117.7M | SEC |
| Q1 2023 | May 3, 2023 | $0.20 | $0.14 | −29.51% | $105.7M | SEC |
| Q4 2022 | Feb 28, 2023 | $0.24 | $0.14 | −41.59% | $103.1M | SEC |
| Q3 2022 | Nov 3, 2022 | $0.23 | $0.30 | +28.21% | $101.7M | SEC |
| Q2 2022 | Aug 3, 2022 | $0.24 | $0.24 | +1.39% | $103.4M | SEC |
| Q1 2022 | May 5, 2022 | $0.23 | $0.20 | −13.68% | $93.7M | SEC |
| Q4 2021 | Feb 15, 2022 | $0.23 | $0.26 | +15.56% | $98.8M | SEC |
| Q3 2021 | Nov 3, 2021 | $0.22 | $0.24 | +11.63% | $96.1M | SEC |
Quarterly revenue
Frequently asked questions
When did Corcept Therapeutics (CORT) last report earnings?
Corcept Therapeutics last reported on Jul 29, 2026, covering fiscal Q2 2026.
Did CORT beat earnings estimates?
Yes. Corcept Therapeutics reported EPS of $0.36 for Q2 2026 against a $0.02 estimate — a 1381.48% beat.
How much revenue did CORT report last quarter?
Corcept Therapeutics reported $256.1M in revenue for Q2 2026, against a consensus estimate of $221.1M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.